/OTLK
OTLK Stock - Outlook Therapeutics, Inc.
Healthcare|BiotechnologyNASDAQ
$2.01-2.90%
$0.06 (-2.90%) • Dec 19
53
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.90
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).0
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+-50.2%upside
Target: $1.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for OTLK
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$1.99 – $2.03
TARGET (TP)$1.00
STOP LOSS$1.85
RISK/REWARD1:-6.3
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.18
52W High$3.39
52W Low$0.79
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $1.41T | N/A | N/A | N/A | N/A |
| Gross Profit | $57.20B | $-113,859 | $-44,188 | $-204,694 | $-262,139 |
| Gross Margin | 4.0% | N/A | N/A | N/A | N/A |
| Operating Income | $-67,061,666,000,000 | $-71,703,000 | $-53,126,000 | $-63,071,000 | $-51,727,000 |
| Net Income | $-62,424,863,000,000 | $-75,367,000 | $-58,983,000 | $-66,052,000 | $-53,163,000 |
| Net Margin | -4416.2% | N/A | N/A | N/A | N/A |
| EPS | $-1.79 | $-4.06 | $-4.72 | $-6.23 | $-6.96 |
Company Overview
Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
6
40%
Hold / Neutral
9
60%
Sell / Underperform
0%
Analyst Consensus🔴 Bearish
6 Bullish9 Neutral/Bearish
Price Targets
$9
Average Target
↑ 352.7% Upside
Now
$1
Low
$9
Average
$50
High
Based on 10 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| August 29th 2025 | H.C. Wainwright | Downgrade | Neutral | - |
| August 28th 2025 | Guggenheim | Downgrade | Neutral | - |
| December 2nd 2024 | Chardan Capital Markets | Downgrade | Neutral | - |
| March 27th 2024 | BTIG Research | Upgrade | Buy | $50 |
| February 15th 2024 | Chardan Capital Markets | Upgrade | Buy | $3 |
| January 25th 2024 | Guggenheim | Upgrade | Buy | - |
| December 27th 2023 | CapitalOne | Upgrade | Overweight | $5 |
| August 31st 2023 | H.C. Wainwright | Downgrade | Neutral | $1← $5 |
| August 31st 2023 | Chardan Capital Markets | Downgrade | Neutral | - |
| August 30th 2023 | CapitalOne | Downgrade | Equal Weight | - |
| August 30th 2023 | Guggenheim | Downgrade | Neutral | - |
| August 30th 2023 | Cantor Fitzgerald | Downgrade | Neutral | $1← $4.5 |
| August 30th 2023 | BTIG Research | Downgrade | Neutral | - |
| July 13th 2023 | CapitalOne | Initiation | Overweight | $5 |
| April 3rd 2023 | Guggenheim | Initiation | Buy | $5 |
Earnings History & Surprises
OTLKBeat Rate
44%
Last 18 quarters
Avg Surprise
-10.3%
EPS vs Estimate
Beats / Misses
8/8
2 met exactly
Latest EPS
$-0.22
Q4 2025
EPS Surprise History
Q1 24
+20.0%
$-0.80vs$-1.00
Q2 24
-76.1%
$-1.55vs$-0.88
Q3 24
+21.7%
$-0.83vs$-1.06
Q4 24
+7.2%
$-0.77vs$-0.83
Q1 25
-4.7%
$-0.89vs$-0.85
Q2 25
+27.3%
$-0.40vs$-0.55
Q3 25
-4.8%
$-0.44vs$-0.42
Q4 25
+4.3%
$-0.22vs$-0.23
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 13, 2026 | — | — | — | — |
Q1 2026 | Feb 13, 2026 | $-0.21 | — | — | — |
Q4 2025 | Dec 19, 2025 | $-0.23 | $-0.22 | +4.3% | ✓ BEAT |
Q3 2025 | Aug 14, 2025 | $-0.42 | $-0.44 | -4.8% | ✗ MISS |
Q2 2025 | May 15, 2025 | $-0.55 | $-0.40 | +27.3% | ✓ BEAT |
Q1 2025 | Feb 14, 2025 | $-0.85 | $-0.89 | -4.7% | ✗ MISS |
Q4 2024 | Dec 27, 2024 | $-0.83 | $-0.77 | +7.2% | ✓ BEAT |
Q3 2024 | Aug 14, 2024 | $-1.06 | $-0.83 | +21.7% | ✓ BEAT |
Q2 2024 | May 15, 2024 | $-0.88 | $-1.55 | -76.1% | ✗ MISS |
Q1 2024 | Feb 14, 2024 | $-1.00 | $-0.80 | +20.0% | ✓ BEAT |
Q4 2023 | Dec 22, 2023 | $-1.00 | $-1.00 | 0.0% | = MET |
Q3 2023 | Aug 14, 2023 | $-0.80 | $-1.60 | -100.0% | ✗ MISS |
Q2 2023 | May 15, 2023 | $-1.20 | $-0.60 | +50.0% | ✓ BEAT |
Q1 2023 | Feb 14, 2023 | $-0.80 | $-1.60 | -100.0% | ✗ MISS |
Q4 2022 | Dec 29, 2022 | $-0.07 | $-0.06 | +14.3% | ✓ BEAT |
Q3 2022 | Aug 10, 2022 | $-1.60 | $-1.60 | 0.0% | = MET |
Q2 2022 | May 13, 2022 | $-1.40 | $-1.80 | -28.6% | ✗ MISS |
Q1 2022 | Feb 14, 2022 | $-1.40 | $-1.60 | -14.3% | ✗ MISS |
Q4 2021 | Dec 22, 2021 | $-1.40 | $-1.60 | -14.3% | ✗ MISS |
Q3 2021 | Aug 13, 2021 | $-1.60 | $-1.40 | +12.5% | ✓ BEAT |
Latest News
Outlook Therapeutics rises on FDA review for wet AMD therapy
📈 PositiveSeeking Alpha•Nov 13, 2025, 03:10 PM•Also:
Outlook Therapeutics Announces Acceptance Of Biologics License Application By FDA For ONS-5010 In Wet AMD
📈 PositiveBenzinga•Nov 13, 2025, 01:31 PM•Also:
Outlook Therapeutics Re-Submits Biologics License Application To FDA For ONS-5010 For Wet AMD
📈 PositiveBenzinga•Nov 3, 2025, 01:43 PM•Also:
HC Wainwright & Co. Reiterates Neutral on Outlook Therapeutics, Maintains $1 Price Target
➖ NeutralBenzinga•Sep 30, 2025, 11:41 AM
Ascendiant Capital Maintains Buy on Outlook Therapeutics, Lowers Price Target to $8
➖ NeutralBenzinga•Sep 22, 2025, 09:30 AM
Outlook Therapeutics Requests FDA Meeting To Clarify Confirmatory Evidence Requirements For ONS-5010 Wet AMD Biologics License Application
➖ NeutralBenzinga•Sep 2, 2025, 12:36 PM•Also:
Guggenheim Downgrades Outlook Therapeutics to Neutral
➖ NeutralBenzinga•Aug 29, 2025, 04:51 PM
Outlook Therapeutics shares are trading lower after HC Wainwright downgraded the stock from Buy to Neutral and announced a $1 price target.
📉 NegativeBenzinga•Aug 29, 2025, 02:53 PM
HC Wainwright & Co. Downgrades Outlook Therapeutics to Neutral, Announces $1 Price Target
📉 NegativeBenzinga•Aug 29, 2025, 12:47 PM
Chardan Capital Maintains Neutral on Outlook Therapeutics, Maintains $3 Price Target
➖ NeutralBenzinga•Aug 28, 2025, 08:39 PM
FDA Declines Outlook Therapeutics' Wet AMD Drug Application In Present Form; Company Pursues Approval Path, Plans EU Market Growth
📉 NegativeBenzinga•Aug 28, 2025, 10:33 AM•Also:
Outlook Therapeutics shares are trading lower after the FDA issued a Complete Response Letter for its resubmitted ONS-5010 BLA.
📉 NegativeBenzinga•Aug 28, 2025, 10:32 AM
Outlook Therapeutics Reports Q3 Revenue
➖ NeutralThe Motley Fool•Aug 14, 2025, 09:34 PM
Outlook Therapeutics drops 17%, prices $13M stock offering
📉 NegativeSeeking Alpha•May 23, 2025, 10:48 AM
Frequently Asked Questions about OTLK
What is OTLK's current stock price?
Outlook Therapeutics, Inc. (OTLK) is currently trading at $2.01 per share. The stock has moved -2.90% today.
What is the analyst price target for OTLK?
The average analyst price target for OTLK is $1.00, based on 1 analyst.
What sector is Outlook Therapeutics, Inc. in?
Outlook Therapeutics, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is OTLK's market cap?
Outlook Therapeutics, Inc. has a market capitalization of $0.09 billion, making it a small-cap company.
Does OTLK pay dividends?
No, Outlook Therapeutics, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorCOEP
Coeptis Therapeutics, Inc.
$14.66
Mkt Cap: $0.1B
CUE
Cue Biopharma, Inc.
$0.27
Mkt Cap: $0.0B
EQ
Equillium, Inc.
$1.15
Mkt Cap: $0.0B
HOWL
Werewolf Therapeutics, Inc.
$0.69
Mkt Cap: $0.0B
IOBT
IO Biotech, Inc.
$0.66
Mkt Cap: $0.0B
IPSC
Century Therapeutics, Inc.
$0.90
Mkt Cap: $0.1B
MDCX
Medicus Pharma Ltd. Common Stock
$1.69
Mkt Cap: $0.0B
NRXP
NRx Pharmaceuticals, Inc.
$2.37
Mkt Cap: $0.0B
OSTX
OS Therapies Incorporated
$1.54
Mkt Cap: $0.1B
SPRB
Spruce Biosciences, Inc.
$78.74
Mkt Cap: $0.0B
Explore stocks similar to OTLK for comparison